Rare childhood cancer subtype, Ph+ ALL, is found in 3-4% of pediatric cases and 25% of adult cases
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
The launch of HULIO in the United States is an important milestone for Biocon Biologics
Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully
The company is already marketing the 4 mg and 10 mg strengths
Granules India sponsored an initiative to ignite a drug-free revolution and contribute towards an empowered society
The product will be produced at the Eugia Pharma Specialities, Unit-I, Medchal, Malkajgiri District, Telangana, India
Columvi is part of Roche's industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approved Lunsumio to treat follicular lymphoma
Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses
Investment enables development of revolutionary multi-omic platform using super-resolution imaging technology for earlier disease detection and accelerated discovery of therapeutics
Subscribe To Our Newsletter & Stay Updated
